Charles W Ashley1, Arnaud Da Cruz Paula1, Rahul Kumar2, Diana Mandelker2, Xin Pei3, Nadeem Riaz3, Jorge S Reis-Filho2, Britta Weigelt4. 1. Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: weigeltb@mskcc.org.
Abstract
OBJECTIVE: Mutational signatures provide insights into the biological processes shaping tumor genomes and may inform patient therapy. We sought to define the mutational signatures of i) endometrioid and serous endometrial carcinomas (ECs), stratified into the four molecular subtypes, ii) uterine carcinosarcomas, and iii) matched primary and metastatic ECs. METHODS: Whole-exome sequencing MC3 data from primary endometrioid and serous carcinomas (n = 232) and uterine carcinosarcomas (n = 57) from The Cancer Genome Atlas (TCGA), and matched primary and metastatic ECs (n = 61, 26 patients) were reanalyzed, subjected to mutational signature analysis using deconstructSigs, and correlated with clinicopathologic and genomic data. RESULTS: POLE (ultramutated) and MSI (hypermutated) molecular subtypes displayed dominant mutational signatures associated with POLE mutations (15/17 cases) and microsatellite instability (55/65 cases), respectively. Most endometrioid and serous carcinomas of copy-number low (endometrioid) and copy-number high (serous-like) molecular subtypes, and carcinosarcomas displayed a dominant aging-associated signature 1. Only 15% (9/60) of copy-number high (serous-like) ECs had a dominant signature 3 (homologous recombination DNA repair deficiency (HRD)-related), a prevalence significantly lower than that found in high-grade serous ovarian carcinomas (54%, p < 0.001) or basal-like breast cancers (46%, p < 0.001). Shifts from aging- or POLE- to MSI-related mutational processes were observed in the progression from primary to metastatic ECs in a subset of cases. CONCLUSIONS: The mutational processes underpinning ECs vary even among tumors of the same TCGA molecular subtype and in the progression from primary to metastatic ECs. Only a minority of copy-number high (serous-like) ECs display genomics features of HRD and would likely benefit from HRD-directed therapies.
OBJECTIVE: Mutational signatures provide insights into the biological processes shaping tumor genomes and may inform patient therapy. We sought to define the mutational signatures of i) endometrioid and serous endometrial carcinomas (ECs), stratified into the four molecular subtypes, ii) uterinecarcinosarcomas, and iii) matched primary and metastatic ECs. METHODS: Whole-exome sequencing MC3 data from primary endometrioid and serous carcinomas (n = 232) and uterinecarcinosarcomas (n = 57) from The Cancer Genome Atlas (TCGA), and matched primary and metastatic ECs (n = 61, 26 patients) were reanalyzed, subjected to mutational signature analysis using deconstructSigs, and correlated with clinicopathologic and genomic data. RESULTS: POLE (ultramutated) and MSI (hypermutated) molecular subtypes displayed dominant mutational signatures associated with POLE mutations (15/17 cases) and microsatellite instability (55/65 cases), respectively. Most endometrioid and serous carcinomas of copy-number low (endometrioid) and copy-number high (serous-like) molecular subtypes, and carcinosarcomas displayed a dominant aging-associated signature 1. Only 15% (9/60) of copy-number high (serous-like) ECs had a dominant signature 3 (homologous recombination DNA repair deficiency (HRD)-related), a prevalence significantly lower than that found in high-grade serous ovarian carcinomas (54%, p < 0.001) or basal-like breast cancers (46%, p < 0.001). Shifts from aging- or POLE- to MSI-related mutational processes were observed in the progression from primary to metastatic ECs in a subset of cases. CONCLUSIONS: The mutational processes underpinning ECs vary even among tumors of the same TCGA molecular subtype and in the progression from primary to metastatic ECs. Only a minority of copy-number high (serous-like) ECs display genomics features of HRD and would likely benefit from HRD-directed therapies.
Authors: Antonio Travaglino; Antonio Raffone; Annarita Gencarelli; Antonio Mollo; Maurizio Guida; Luigi Insabato; Angela Santoro; Gian Franco Zannoni; Fulvio Zullo Journal: Pathol Oncol Res Date: 2020-05-29 Impact factor: 3.201
Authors: Beryl L Manning-Geist; Ying L Liu; Kelly A Devereaux; Arnaud Da Cruz Paula; Qin C Zhou; Weining Ma; Pier Selenica; Ozge Ceyhan-Birsoy; Lea A Moukarzel; Timothy Hoang; Sushmita Gordhandas; Maria M Rubinstein; Claire F Friedman; Carol Aghajanian; Nadeem R Abu-Rustum; Zsofia K Stadler; Jorge S Reis-Filho; Alexia Iasonos; Dmitriy Zamarin; Lora H Ellenson; Yulia Lakhman; Diana L Mandelker; Britta Weigelt Journal: Clin Cancer Res Date: 2022-10-03 Impact factor: 13.801
Authors: Ying L Liu; Pier Selenica; Qin Zhou; Alexia Iasonos; Margaret Callahan; Noah Z Feit; Julia Boland; Ignacio Vazquez-Garcia; Diana Mandelker; Ahmet Zehir; Robert A Burger; Daniel J Powell; Claire Friedman; Karen Cadoo; Rachel Grisham; Jason A Konner; Roisin E O'Cearbhaill; Carol Aghajanian; Jorge S Reis-Filho; Britta Weigelt; Dmitriy Zamarin Journal: JCO Precis Oncol Date: 2020-06-16
Authors: Marina Stasenko; Irina Tunnage; Charles W Ashley; Maria M Rubinstein; Alicia J Latham; Arnaud Da Cruz Paula; Jennifer J Mueller; Mario M Leitao; Claire F Friedman; Vicky Makker; Robert A Soslow; Deborah F DeLair; David M Hyman; Dimitriy Zamarin; Kaled M Alektiar; Carol A Aghajanian; Nadeem R Abu-Rustum; Britta Weigelt; Karen A Cadoo Journal: Gynecol Oncol Date: 2019-11-19 Impact factor: 5.482
Authors: Olga T Filippova; Pier Selenica; Fresia Pareja; Mahsa Vahdatinia; Yingjie Zhu; Xin Pei; Nadeem Riaz; Kara Long Roche; Dennis S Chi; Nadeem R Abu-Rustum; Lora H Ellenson; Jorge S Reis-Filho; Dmitriy Zamarin; Britta Weigelt Journal: Gynecol Oncol Date: 2021-03-03 Impact factor: 5.482
Authors: Alaa Salah Jumaah; Hawraa Sahib Al-Haddad; Mais Muhammed Salem; Katherine Ann McAllister; Akeel Abed Yasseen Journal: J Pathol Transl Med Date: 2021-04-14
Authors: Arnaud Da Cruz Paula; Deborah F DeLair; Lorenzo Ferrando; Daniel J Fix; Robert A Soslow; Kay J Park; Sarah Chiang; Jorge S Reis-Filho; Ahmet Zehir; Mark T A Donoghue; Michelle Wu; David N Brown; Rajmohan Murali; Claire F Friedman; Dmitriy Zamarin; Vicky Makker; Jennifer J Mueller; Mario M Leitao; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt Journal: Gynecol Oncol Date: 2021-02-21 Impact factor: 5.482